‘A matter of life and death for me’: Millions of Americans who rely on cheap drugs from Canada could see prices soar due to new federal rule
Critics say the Oct. 22 shipping change could disrupt cross-border prescriptions even as the White House makes lower drug prices a priority
A new U.S. customs rule taking effect soon could cause a surge in drug prices for millions of Americans who currently purchase cheaper medications from Canada, a move that has drawn criticism from Democrats and some Republicans as voters focus on the cost of living ahead of midterms. The rule targets the de minimis exemption, which previously permitted low-value shipments to pass through customs with less scrutiny.
As of October 22, this exemption will no longer be applicable, and medications mailed from abroad will require additional data and a bond guarantee. While the rule does not explicitly target Canadian drugs, it could result in delays, rejections, or significantly more difficulty obtaining medications for Americans who rely on low-cost drugs from the border country.
Roughly 2.3 million Americans buy their drugs abroad, according to a 2020 study by JAMA Network. President Donald Trump has made lowering drug prices a top priority, implementing various strategies, including most-favored-nation drug deals with pharmaceutical companies and the establishment of a discounted-drug website, TrumpRx.
However, some experts warn that the new rule may undermine the effectiveness of Trump's drug pricing initiatives, as costs for certain medications imported from Canada could skyrocket, leaving patients with limited affordable options.
Rewritten by urgent.news; may contain errors — check the original.
Sources: fortune.com · qz.com